Private Equity Bets Big on Drug Manufacturers Amid Supply Chain Shifts

Investors are pouring billions into CMOs drawn by steady revenues, demand, and a push for resilient U.S.-based production.

Private equity (PE) firms are investing heavily in contract manufacturing organizations (CMOs) like PCI Pharma Services and Catalent, drawn by surging demand for fast, cost-efficient drug production, particularly for high-growth therapies such as Ozempic and Wegovy. According to the Wall Street Journal, investors view CMOs as a prime value play and a strategic growth opportunity in the healthcare supply chain.

This trend reflects a broader shift toward strengthening domestic manufacturing. Ongoing drug shortages and geopolitical pressures have underscored the need for more diversified and U.S.-based capacity, and PE investors are betting that both regulators and pharmaceutical companies will pay a premium for secure, resilient production partners.

Private equity’s role in healthcare delivery is complex. On one hand, it provides essential capital and operational know-how, but on the other, it raises concerns for policymakers, providers, and patients. The sector’s short-term, profit-driven approach can clash with healthcare’s long-term mission of patient care, sometimes resulting in reduced access or quality.

In contrast, CMOs present a different kind of opportunity for PE. With contract-based, steady revenue and strong demand in areas like biologics, they offer a more predictable investment profile. The industry’s fragmentation makes it ripe for consolidation, while ongoing supply chain volatility has increased the value of domestic and specialized manufacturing capacity.

About the Author

Daniel Beaird

Daniel Beaird

Head of Content and Editor-in-Chief

Daniel Beaird is Head of Content and Editor-in-Chief of Healthcare Purchasing News (HPN), where he leads editorial strategy and content development across print, digital, podcasts, webinars, and educational programming. His coverage focuses on healthcare supply chain, sterile processing, infection prevention, and perioperative services, connecting industry developments with the purchasing and operational decisions that shape patient care. 

Before joining HPN, he served as Senior Editor of The Journal of Healthcare Contracting, covering health system supply chain strategy, industry partnerships and the evolving business of healthcare. 

He holds a bachelor’s degree in journalism from the University of Georgia and is based in Atlanta. 

Sign up for our eNewsletters
Get the latest news and updates